How PIQRAY May Help

PIQRAY® (alpelisib) tablets + fulvestrant

How Can PIQRAY Help?

PIK3CA mutations have been linked to cancer growth. But together, PIQRAY and fulvestrant can help slow the progression of HR+, HER2- mBC with a PIK3CA mutation.

 

PIQRAY was studied in a clinical trial that included 572 postmenopausal women, or men, with HR+, HER2- mBC who had progressed on or after an aromatase inhibitor (a hormone therapy). Of the 341 people who tested positive for the PIK3CA mutation, 169 took PIQRAY + fulvestrant, while 172 took fulvestrant alone.

 

Live Longer Without Disease Progression

People who tested positive for a PIK3CA mutation and took PIQRAY + fulvestrant lived progression-free for almost twice as long as those who took fulvestrant alone. 

Median time people with a PIK3CA mutation lived without disease progression from the start of PIQRAY + fulvestrant treatment Median time people with a PIK3CA mutation lived without disease progression from the start of PIQRAY + fulvestrant treatment

Shrinks Tumors

Additional results of the trial showed that PIQRAY and fulvestrant worked together to shrink tumors in people with a PIK3CA mutation who had tumors large enough to measure. Of the 262 people with measurable disease, 126 took PIQRAY + fulvestrant and 136 took fulvestrant alone.

 

Twice as many people with a PIK3CA mutation who had tumors large enough to measure who took PIQRAY + fulvestrsant had tumors that shrank or disappeared vs those who took fulvestrant alone. Twice as many people with a PIK3CA mutation who had tumors large enough to measure who took PIQRAY + fulvestrsant had tumors that shrank or disappeared vs those who took fulvestrant alone.